NRX-101 Archives - NRx Pharmaceuticals

Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

Dec. 5, 2024

Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals, presents at Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals, presents at NobleCon20 – Noble Capital Markets’ Twentieth Annual Emerging Growth Equity Conference at Florida Atlantic University on Tuesday December 3, 2024

Sep. 29, 2024

The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals

The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing IV Ketamine and it’s treatment for acute suicidality, anti-depressant oral medication NRX-101 and the launch of Hope Therapeutics.

Jul. 9, 2024

The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals

The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing IV Ketamine and it’s treatment for acute suicidality, anti-depressant oral medication NRX-101 and the launch of Hope Therapeutics.

The Big Biz Show interviews Jonathan C. Javitt, NRx Pharmaceuticals

May. 13, 2024

The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals

The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing suicidal ideation, NRx-100, IV Ketamine, and the promising findings in Phase 2b/3 clinical trial of NRX-101 vs. Lurasidone for treatment of Suicidal Bipolar Depression.

Mar. 19, 2024

One America News interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals

One America News interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing how Ketamine can reduce Suicidal Ideation.

Mar. 3, 2024

The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals

The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing IV Ketamine and it’s treatment for acute suicidality, anti-depressant oral medication NRX-101 and the launch of Hope Therapeutics.

Jan. 18, 2024

David Meltzer of “Office Hours” interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals to discuss the anti-depressant effect of Ketamine

David Meltzer of “Office Hours” interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals to discuss the anti-depressant effect of Ketamine.

Jonathan Javitt, NRx Pharmaceuticals, gives keynote address at Sachs Neuroscience Innovation Forum

Jan. 10, 2024

Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals, gives the keynote address “Ketamine for Suicidal Depression: The Benefits are Clear, But So are the Risks,” at the Sachs Neuroscience Innovation Forum in San Francisco, CA on January 7, 2024

Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals, gives the keynote address “Ketamine for Suicidal Depression: The Benefits are Clear, But So are the Risks,” at the Sachs Neuroscience Innovation Forum in San Francisco, CA on January 7, 2024.

Dec. 27, 2023

The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H., Chairmain & Chief Scientist, NRx Pharmaceuticals to discuss the anti-depressant effect of Ketamine

The Big Biz Show interviews Jonathan C. Javitt, M.D., M.P.H., Chairman and Chief Scientist, NRx Pharmaceuticals, discussing the anti-depressant effect of Ketamine.

Cookie	Duration	Description
_wpfuuid	11 years	This cookie is used by the WPForms WordPress plugin. The cookie is used to allows the paid version of the plugin to connect entries by the same user and is used for some additional features like the Form Abandonment addon.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
nlbi_1816097	session	A load balancing cookie set to ensure requests by a client are sent to the same origin server.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
visid_incap_1816097	1 year	SiteLock sets this cookie to provide cloud-based website security services.

Cookie	Duration	Description
_jsuid	1 year	This cookie contains random number which is generated when a visitor visits the website for the first time. This cookie is used to identify the new visitors to the website.
cluid	1 year	This cookie is used for websites which is having multiple domains to identify the same visitor across multiple domains.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
mo_has_visited	11 years	This cookie is used for setting an unique ID for the visitor which helps to get the accurate number of specific visitor on the website.
mo_is_new	session	This cookie is used for counting the new visitors to the website by assigning a unique visitor ID.
mo_page_views_counter	session	This cookie is used for counting the new visitors to the website by assigning a unique visitor ID.

Cookie	Duration	Description
c	6 months 2 days	This cookie is set by Rubicon Project to control synchronization of user identification and exchange of user data between various ad services.
uuid	1 year 27 days	MediaMath sets this cookie to avoid the same ads from being shown repeatedly and for relevant advertising.
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Cookie	Duration	Description
incap_ses_1371_1816097	session	No description
unpoco_101344884	1 day	No description